These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 7014234)

  • 1. Granulocyte function in human allogenic marrow graft recipients.
    Sosa R; Weiden PL; Storb R; Syrotuck J; Thomas ED
    Exp Hematol; 1980 Nov; 8(10):1183-9. PubMed ID: 7014234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defective neutrophil chemotaxis in bone marrow transplant patients.
    Clark RA; Johnson FL; Klebanoff SJ; Thomas ED
    J Clin Invest; 1976 Jul; 58(1):22-31. PubMed ID: 777029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
    Jacobsen N; Badsberg JH; Lönnqvist B; Ringdén O; Volin L; Rajantie J; Nikoskelainen J; Keiding N
    Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human herpes virus-6 infection in marrow graft recipients: role in pathogenesis of graft-versus-host disease. Newcastle upon Tyne Bone Marrow Transport Group.
    Appleton AL; Sviland L; Peiris JS; Taylor CE; Wilkes J; Green MA; Pearson AD; Kelly PJ; Malcolm AJ; Proctor SJ
    Bone Marrow Transplant; 1995 Dec; 16(6):777-82. PubMed ID: 8750269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute graft-versus-host disease after allogeneic bone marrow transplantation.
    Perreault C; Gyger M; Boileau J; Bonny Y; Cousineau S; Lacombe M; Lavallee R; Tawil E; D'Angelo G
    Can Med Assoc J; 1983 Nov; 129(9):969-74. PubMed ID: 6367917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
    J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.
    Anderson D; DeFor T; Burns L; McGlave P; Miller J; Wagner J; Weisdorf D
    Biol Blood Marrow Transplant; 2003 Jan; 9(1):52-9. PubMed ID: 12533742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on cellular inhibition and serum-blocking factors in 28 human patients given marrow grafts from HLA identical siblings.
    Tsoi MS; Storb R; Weiden PL; Thomas ED
    J Immunol; 1977 May; 118(5):1799-805. PubMed ID: 16061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe hematopoietic alterations in vitro, in bone marrow transplant recipients who develop graft-versus-host disease.
    Martínez-Jaramillo G; Gómez-Morales E; Sánchez-Valle E; Mayani H
    J Hematother Stem Cell Res; 2001 Jun; 10(3):347-54. PubMed ID: 11454310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
    Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
    Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transition of T cell receptor gamma/delta expressing double negative (CD4-/CD8-) lymphocytes after allogeneic bone marrow transplantation.
    Yabe M; Yabe H; Hattori K; Hinohara T; Morimoto T; Kato S; Kusunoki A
    Bone Marrow Transplant; 1994 Nov; 14(5):741-6. PubMed ID: 7889006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolactin: a possible mediator of graft-versus-host disease following allogeneic bone marrow transplantation in humans.
    Hinterberger-Fischer M; Kier P; Spona J; Sebesta C; Tiefengraber E; Habertheuer KH; Ruckser R; Schmid A; Kalhs P; Lechner K
    Bone Marrow Transplant; 1994 Sep; 14(3):403-6. PubMed ID: 7994262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gluckman E; Reiffers J; Vernant JP; Jouet JP; Harrousseau JL; Fiere D; Bacigalupo A; Frassoni F; Gorin NC
    Bone Marrow Transplant; 1996 Nov; 18(5):921-9. PubMed ID: 8932846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources.
    Rocha V; Wagner JE; Sobocinski KA; Klein JP; Zhang MJ; Horowitz MM; Gluckman E
    N Engl J Med; 2000 Jun; 342(25):1846-54. PubMed ID: 10861319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Significance of donors treatment with combination of recombinant human interleukin-11 and recombinant human granulocyte-colony stimulating factor in reduction of incidence of lethal grafts versus host disease after allogeneic bone marrow transplantation].
    Zhao J; Zhao XY; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(35):2497-502. PubMed ID: 16321278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
    Lin Q; Dong M; Wang QM; Wen JY; Wu XY
    Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic bone marrow transplantation for acute myeloblastic leukaemia in remission: risk factors for long-term morbidity and mortality.
    Robin M; Guardiola P; Dombret H; Baruchel A; Esperou H; Ribaud P; Devergie A; Gluckman E; Socié G
    Bone Marrow Transplant; 2003 May; 31(10):877-87. PubMed ID: 12748664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of recombinant human granulocyte colony-stimulating factor in children given allogeneic bone marrow transplantation for acute or chronic leukemia.
    Locatelli F; Pession A; Zecca M; Bonetti F; Prete L; Carrà AM; Prete A; Montagna D; Comoli P; Taibi RM; Paolucci G
    Bone Marrow Transplant; 1996 Jan; 17(1):31-7. PubMed ID: 8673051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro sensitivity of post-bone marrow transplantation CFU-GM and BFU-E to TNF-alpha and IFN-gamma.
    Papadakis V; Ferguson KF; Heller G; Kernan NA
    Exp Hematol; 1995 Dec; 23(14):1422-30. PubMed ID: 8542927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.